Xeris Pharmaceuticals | XERS - Gross Profit On Sales


Xeris Pharmaceuticals reported $63.38M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Celltrion KRW 626.11B 81.75B Sep/2025
Cspc Pharmaceutical CNY 4.34B 333.68M Sep/2025
Deva Holding AS TRY 1.32B 235.77M Sep/2023
Dianthus Therapeutics USD 396K 203K Sep/2025
Divis Laboratories Ltd INR 16.59B 2.05B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Kangmei Pharma CNY 270.29M 20.26M Sep/2025
Knight Therapeutics CAD 44.83M 9.96M Jun/2025
Laboratorios Farma EUR 105.28M 177.08M Jun/2025
Medical Developments International AUD 7.35M 7.37M Jun/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Neuren Pharmaceuticals AUD 6.69M 6.37M Jun/2025
Organigram Holdings CAD 31.84M 23.88M Sep/2025
Pacira USD 142.25M 11.34M Dec/2025
Perrigo USD 362.2M 14.9M Dec/2025
Pharma Mar EUR 33.36M 20.25M Sep/2025
Qiagen NV USD 325.27M 19.53M Dec/2025
Sartorius EUR 393.2M 23M Sep/2025
Sino Biopharmaceutical CNY 10.5B 2.53B Dec/2024
Supernus Pharmaceuticals USD 164.04M 15.23M Dec/2025
Tilray USD 67.63M 15.62M Mar/2025
Zz Pientze Pharmaceu CNY 296.13M 1.1B Jun/2025